Viral Vectors and Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors and Plasmid DNA), By Workflow, By Application, By End-Use, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5520
|
Published Date
July 2026
|
Pages
325
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Viral Vectors and Plasmid DNA Manufacturing Market size was valued at USD 6,590.2 Million in 2025, expanding to a CAGR of 15.1% from 2026 to 2033.
Viral vectors and plasmid DNA manufacturing involves the production of specialized genetic materials that are essential for the development of gene therapies, cell therapies, vaccines, and other advanced biologic medicines. Plasmid DNA serves as the foundational genetic template, carrying the therapeutic genetic information and acting as a critical starting material for the production of viral vectors. Viral vectors are genetically engineered viruses designed to safely deliver therapeutic genes into targeted cells while minimizing the risk of causing disease. These components are indispensable in modern biotechnology, enabling precise gene delivery for the treatment of inherited disorders, cancers, and other complex diseases.
According to the World Health Organization (WHO), non-communicable diseases account for approximately 74% of all deaths globally, while the growing prevalence of rare genetic disorders and cancer continues to increase demand for innovative treatment approaches. This rising healthcare burden, combined with significant investments in gene therapy research and advanced biologics, is driving the expansion of viral vector and plasmid DNA manufacturing. As the number of clinical trials and commercial gene and cell therapy products continues to grow worldwide, the need for high-quality, scalable, and regulatory-compliant manufacturing capabilities is expected to increase substantially.
Viral Vectors and Plasmid DNA Manufacturing Market- Market Dynamics
Advancements in cell and gene therapies, next-generation vaccines, and the increasing adoption of automated manufacturing technologies are expected to drive market growth.
The growth of the viral vectors and plasmid DNA manufacturing market is primarily driven by the rapid advancement of gene-based therapies, cell-based therapies, and next-generation vaccine technologies. As biotechnology and pharmaceutical companies increasingly focus on precision medicine approaches that target diseases through genetic modification and targeted biological intervention, the demand for high-quality viral vectors and plasmid DNA continues to rise. These materials play a fundamental role in delivering genetic information into cells, making them essential tools in modern biopharmaceutical research, clinical development, and commercial-scale production. According to global genomic research insights, more than 2,000 gene and cell therapy candidates are currently in various stages of clinical development worldwide, significantly increasing the need for scalable and reliable manufacturing of viral vectors and plasmid DNA.
To improve efficiency and support growing production requirements, manufacturers are increasingly adopting automated manufacturing platforms, single-use bioprocessing systems, and advanced purification technologies. These innovations help reduce production time, minimize contamination risks, and streamline overall manufacturing workflows. In parallel, contract development and manufacturing organizations (CDMOs) are expanding their production capacities through facility expansions, strategic investments, and collaborations with biotechnology and pharmaceutical companies to meet rising outsourcing demand. Additionally, ongoing advancements in next-generation viral vectors are enhancing safety profiles, improving targeted delivery, and increasing gene transfer efficiency. As the industry continues to evolve, the expanding pipeline of gene and cell therapies is expected to sustain strong demand for viral vectors and plasmid DNA manufacturing solutions.
Viral Vectors and Plasmid DNA Manufacturing Market- Segmentation Analysis:
The Global Viral Vectors and Plasmid DNA Manufacturing Market is segmented on the basis of Product Type, Workflow, Application, End-Use, and Region.
The viral vectors and plasmid DNA manufacturing market is segmented by product type into viral vectors and plasmid DNA, with the viral vectors segment accounting for a significant share of overall revenue. Viral vectors serve as the primary delivery systems in gene therapy, cell therapy, and advanced vaccine development platforms. They play a critical role in transporting therapeutic genetic material into targeted cells, enabling precise gene expression and treatment of a wide range of genetic and acquired diseases. Due to their essential function in modern biopharmaceutical applications, viral vectors remain a cornerstone of clinical research and therapeutic innovation.
According to the World Health Organization (WHO), non-communicable diseases account for nearly 74% of global deaths annually, highlighting the urgent need for advanced treatment approaches such as gene and cell therapies. This rising global disease burden, along with increasing clinical research in genetic medicine, is driving the demand for scalable and high-quality viral vector production. As a result, investments in viral vector manufacturing technologies continue to grow, supporting the expansion of innovative therapeutic pipelines worldwide.
Viral Vectors and Plasmid DNA Manufacturing Market- Geographical Insights
The viral vectors and plasmid DNA manufacturing market demonstrates strong regional growth, with North America accounting for a dominant share due to its well-established biotechnology ecosystem, strong pipeline of advanced therapy developers, extensive research infrastructure, and significant funding for gene and cell therapy programs. The region continues to benefit from high levels of clinical research activity and early adoption of innovative biomanufacturing technologies, which collectively strengthen its leadership position in the global market. According to the World Health Organization (WHO), the increasing global burden of genetic disorders and chronic diseases is accelerating demand for advanced therapeutic solutions, further supporting growth in North America’s biopharmaceutical manufacturing sector.
Europe also represents a key market, supported by growing investments in advanced therapeutic platforms, expanding biomanufacturing capabilities, and strong collaboration between academic institutions, research organizations, and industry players. The region’s focus on innovation in biotechnology and regulatory support for advanced therapies continues to enhance its market position. In Asia-Pacific, rapid market expansion is being driven by the development of new GMP-compliant manufacturing facilities, the growing presence of contract development and manufacturing organizations (CDMOs), and the increasing adoption of automated and digitally enabled bioprocessing technologies. These factors are collectively strengthening the region’s role as an emerging hub for cost-efficient and scalable viral vector and plasmid DNA production.
Canada Viral Vectors and Plasmid DNA Manufacturing Market- Key Insights
Canada is emerging as a key contributor to the viral vectors and plasmid DNA manufacturing market, supported by its rapidly growing biotechnology sector, strong research ecosystem, and increasing investments in advanced therapeutic development. The country’s focus on strengthening and localizing the supply chain for next-generation therapies is further encouraging the expansion of domestic manufacturing capabilities. Biotechnology companies and research organizations are increasingly investing in automation technologies, digital biomanufacturing systems, and scalable production platforms to enhance operational efficiency and reduce reliance on external suppliers.
In addition, strong collaborations between biotechnology firms, academic research institutions, and healthcare organizations are accelerating innovation, knowledge sharing, and technology transfer across the sector. According to the World Health Organization (WHO), the rising global burden of chronic and genetic diseases is driving increased demand for advanced therapeutic solutions, including gene and cell therapies. This, in turn, is contributing to higher demand for high-quality viral vectors in Canada, as the country continues to expand its presence in the global advanced biomanufacturing landscape.
Viral Vectors and Plasmid DNA Manufacturing Market- Competitive Landscape:
The competitive landscape of the viral vectors and plasmid DNA manufacturing market is marked by the expansion of capabilities among biotechnology companies, specialized manufacturers, and contract development and manufacturing organizations (CDMOs), all of which are supporting the rapidly growing field of advanced therapies. Industry participants are investing in new manufacturing facilities, upgrading existing GMP-compliant sites, and adopting advanced production technologies to improve scalability, efficiency, and overall process reliability. In addition, many companies are strengthening their market position through strategic partnerships, acquisitions, and collaborations with biotech firms. As more gene and cell therapies progress toward commercialization, demand for reliable large-scale viral vector and plasmid DNA manufacturing services is expected to increase, intensifying competition across the sector.
Recent Developments:
- In March 2025, WuXi Biologics introduced the EffiX™ microbial expression platform, an advanced high-productivity system designed to optimize recombinant protein and plasmid DNA production. The platform aims to improve manufacturing yields and enhance process scalability.
- In June 2025, ProBio inaugurated its new 128,000-square-foot Cell and Gene Therapy Center of Excellence in Hopewell, New Jersey. The GMP-compliant facility expands the company’s manufacturing capabilities for plasmid DNA, adeno-associated virus (AAV) vectors, and lentiviral vectors, enabling increased support for clinical development programs.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS
- Lonza
- Aldevron
- ViroCell Biologics
- Andelyn Biosciences
- VGXI, Inc.
- Avid Bioservices
- Thermo Fisher Scientific
- WuXi Biologics
- Catalent Inc.
- AGC Biologics
- Fujifilm Diosynth Biotechnologies
- Cobra Biologics
- Oxford Biomedica
- Takara Bio
- Charles River Laboratories
- Merck KGaA
- Sartorius
- GenScript Biotech
- RegenxBio Inc.
- SIRION Biotech
- Others
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2020-2033
- Viral Vectors
- Adeno-Associated Virus (AAV)
- Lentivirus
- Adenovirus
- Retrovirus
- Plasmid DNA
- Research-Grade Plasmid DNA
- GMP-Grade Plasmid DNA
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2020-2033
- Upstream Manufacturing
Downstream Manufacturing
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2020-2033
- Cell Therapy
- Gene Therapy
- Vaccine Development
- Others
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END-USE- MARKET ANALYSIS, 2020-2033
- Pharmaceutical & Biotechnology Companies
- CDMOs
- Academic & Research Institutes
- Others
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2020-2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Viral Vectors and Plasmid DNA Manufacturing Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Viral Vectors and Plasmid DNA Manufacturing Market Snippet by Product Type
2.1.2. Viral Vectors and Plasmid DNA Manufacturing Market Snippet by Workflow
2.1.3. Viral Vectors and Plasmid DNA Manufacturing Market Snippet by Application
2.1.4. Viral Vectors and Plasmid DNA Manufacturing Market Snippet by End-Use
2.1.5. Viral Vectors and Plasmid DNA Manufacturing Market Snippet by Country
2.1.6. Viral Vectors and Plasmid DNA Manufacturing Market Snippet by Region
2.2. Competitive Insights
3. Viral Vectors and Plasmid DNA Manufacturing Key Market Trends
3.1. Viral Vectors and Plasmid DNA Manufacturing Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Viral Vectors and Plasmid DNA Manufacturing Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Viral Vectors and Plasmid DNA Manufacturing Market Opportunities
3.4. Viral Vectors and Plasmid DNA Manufacturing Market Future Trends
4. Viral Vectors and Plasmid DNA Manufacturing Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Viral Vectors and Plasmid DNA Manufacturing Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Viral Vectors and Plasmid DNA Manufacturing Market Landscape
6.1. Viral Vectors and Plasmid DNA Manufacturing Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Viral Vectors and Plasmid DNA Manufacturing Market – By Product Type
7.1. Overview
7.1.1. Segment Share Analysis, By Product Type, 2025 & 2033 (%)
7.1.2. Viral Vectors
7.1.2.1. Adeno-Associated Virus (AAV)
7.1.2.2. Lentivirus
7.1.2.3. Adenovirus
7.1.2.4. Retrovirus
7.1.3. Plasmid DNA
7.1.3.1. Research-Grade Plasmid DNA
7.1.3.2. GMP-Grade Plasmid DNA
8. Viral Vectors and Plasmid DNA Manufacturing Market – By Workflow
8.1. Overview
8.1.1. Segment Share Analysis, By Workflow, 2025 & 2033 (%)
8.1.2. Upstream Manufacturing
8.1.3. Downstream Manufacturing
9. Viral Vectors and Plasmid DNA Manufacturing Market – By Application
9.1. Overview
9.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
9.1.2. Cell Therapy
9.1.3. Gene Therapy
9.1.4. Vaccine Development
9.1.5. Others
10. Viral Vectors and Plasmid DNA Manufacturing Market – By End-Use
10.1. Overview
10.1.1. Segment Share Analysis, By End-Use, 2025 & 2033 (%)
10.1.2. Pharmaceutical & Biotechnology Companies
10.1.3. CDMOs
10.1.4. Academic & Research Institutes
10.1.5. Others
11. Viral Vectors and Plasmid DNA Manufacturing Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Viral Vectors and Plasmid DNA Manufacturing Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Viral Vectors and Plasmid DNA Manufacturing Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Viral Vectors and Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Viral Vectors and Plasmid DNA Manufacturing Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Viral Vectors and Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Workflow, 2020 - 2033 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Viral Vectors and Plasmid DNA Manufacturing Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Lonza
12.2.2. Aldevron
12.2.3. ViroCell Biologics
12.2.4. Andelyn Biosciences
12.2.5. VGXI, Inc.
12.2.6. Avid Bioservices
12.2.7. Thermo Fisher Scientific
12.2.8. WuXi Biologics
12.2.9. Catalent Inc.
12.2.10. AGC Biologics
12.2.11. Fujifilm Diosynth Biotechnologies
12.2.12. Cobra Biologics
12.2.13. Oxford Biomedica
12.2.14. Takara Bio
12.2.15. Charles River Laboratories
12.2.16. Merck KGaA
12.2.17. Sartorius
12.2.18. GenScript Biotech
12.2.19. RegenxBio Inc.
12.2.20. SIRION Biotech
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS
- Lonza
- Aldevron
- ViroCell Biologics
- Andelyn Biosciences
- VGXI, Inc.
- Avid Bioservices
- Thermo Fisher Scientific
- WuXi Biologics
- Catalent Inc.
- AGC Biologics
- Fujifilm Diosynth Biotechnologies
- Cobra Biologics
- Oxford Biomedica
- Takara Bio
- Charles River Laboratories
- Merck KGaA
- Sartorius
- GenScript Biotech
- RegenxBio Inc.
- SIRION Biotech
- Others
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2020-2033
- Viral Vectors
- Adeno-Associated Virus (AAV)
- Lentivirus
- Adenovirus
- Retrovirus
- Plasmid DNA
- Research-Grade Plasmid DNA
- GMP-Grade Plasmid DNA
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2020-2033
- Upstream Manufacturing
Downstream Manufacturing
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2020-2033
- Cell Therapy
- Gene Therapy
- Vaccine Development
- Others
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END-USE- MARKET ANALYSIS, 2020-2033
- Pharmaceutical & Biotechnology Companies
- CDMOs
- Academic & Research Institutes
- Others
GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2020-2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
